Study finds mixed results for fluorescence biomodulation in pet wounds

A newly published clinical trial in Frontiers in Veterinary Science found that fluorescence biomodulation did not deliver a consistent measurable advantage when added to standardized wound management for open wounds in dogs and cats. The prospective, randomized, within-wound controlled study enrolled 15 client-owned animals and compared treated and untreated portions of the same wound over a follow-up period of up to four weeks. Across planimetric, qualitative, histologic, and immunohistochemical measures, the differences were not statistically significant. (frontiersin.org)

That result matters because fluorescence biomodulation, often delivered commercially through systems such as Phovia, has built momentum in companion animal dermatology and wound care. Reviews of the field have described anti-inflammatory and regenerative mechanisms, while company materials and prior publications have pointed to potential benefits in pyoderma, interdigital furunculosis, surgical wounds, and other skin conditions. A 2024 prospective trial in female dogs after mastectomy, for example, reported improved wound-healing quality scores and lower inflammatory indices in treated portions of the incision. (pmc.ncbi.nlm.nih.gov)

The new study was designed to test whether those signals would hold up in a more clinically diverse wound population. Animals referred to a university teaching hospital between December 2023 and July 2025 were eligible if they had open wounds from traumatic tissue loss, burns, surgical dehiscence, or infection. Each wound was divided into two portions, one randomly assigned to weekly fluorescence biomodulation and the other to control treatment, while both sides received standardized wound care based on the TIME framework. The fluorescence protocol used a chromophore gel plus blue LED illumination delivered twice per session, one minute apart. (frontiersin.org)

On the main outcomes, the treated and control portions tracked closely. The paper reports no statistically significant differences in percentage wound area reduction, qualitative healing scores, or semiquantitative histologic and immunohistochemical findings. The median paired difference in wound area reduction was 0.0%, and complete closure during follow-up also did not differ significantly between sides. Even so, the response pattern was uneven rather than uniformly negative: seven wounds favored the treated portion, six favored the control portion, and two were essentially equivalent. Exploratory post hoc analyses suggested a possible trend toward earlier wound area reduction when treatment started in more recent wounds, but those findings were also not statistically significant. (frontiersin.org)

The paper’s discussion places the findings in the context of a broader, mixed evidence base for photobiomodulation in veterinary medicine. The authors note that controversy persists around clinical efficacy, in part because outcomes can be dose-dependent and protocols are not standardized across studies. They also point to conflicting findings in other veterinary settings, including dentistry, and suggest that any benefit may be context-dependent. That interpretation lines up with broader reviews, which describe promise for photobiomodulation but also emphasize variation in devices, wavelengths, treatment intervals, and case selection. (frontiersin.org)

Why it matters: For practicing veterinarians, this is a reminder to separate biologic plausibility from proven clinical effect. Open wound cases in general practice and referral settings are heterogeneous, often involving contamination, delayed presentation, comorbidities, variable tissue viability, and different closure plans. In that environment, an adjunctive light-based therapy may still help selected patients, but this study does not support assuming a reliable across-the-board improvement over good wound-bed preparation and standard care alone. It also suggests practices should be careful in how they frame expectations for pet parents, especially when discussing cost, visit frequency, and likely benefit. (frontiersin.org)

There’s also an antimicrobial stewardship angle. The authors note that stewardship is a critical part of open-wound management and report that wounds in the study showed heterogeneous microbial populations and resistance patterns, yet clinical resolution was achieved through appropriate wound management rather than reliance on antimicrobials alone. That’s notable because commercial messaging around fluorescence biomodulation has sometimes highlighted the possibility of reducing infection risk or supporting reduced antibiotic use. This trial doesn’t rule out that role, but it does suggest the evidence remains indication-specific rather than universal. (frontiersin.org)

What to watch: The authors call for prospectively stratified studies focused on healing speed and readiness for closure, and the most plausible next wave of research will likely test narrower case groups, earlier intervention windows, and more standardized protocols rather than broad all-comer wound populations. (frontiersin.org)